Advertisement

Topics

Macitentan Viable for Inoperable Pulmonary Hypertension

09:58 EDT 24 May 2017 | Medscape

An endothelin receptor antagonist is showing promise in the phase 2 MERIT study of patients with chronic thromboembolic pulmonary hypertension, who have few treatment options.
Medscape Medical News

Original Article: Macitentan Viable for Inoperable Pulmonary Hypertension

NEXT ARTICLE

More From BioPortfolio on "Macitentan Viable for Inoperable Pulmonary Hypertension"

Quick Search
Advertisement
 

Relevant Topic

Pulmonary Hypertension
Pulmonary arterial hypertension (PAH) is a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs of affected individuals. Symptoms can range from mild breathles...